{"schema_version":"secwatch.filing_event.v1","accession":"0001799191-23-000006","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.645265+00:00","generated_at":"2026-06-14T18:26:18.313519+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"COO Matthew Miller to depart June 16, 2023; duties assumed by President Virnich","bullets":["Dr. Matthew Miller terminated as COO effective June 16, 2023; severance includes 3 months base salary and healthcare.","Option exercise period extended to May 18, 2024, contingent on signing a general release of claims.","No replacement will be hired; President Dr. Daniel Virnich will absorb COO responsibilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001799191-23-000006","json":"https://secwatch.observer/filing/0001799191-23-000006.json","markdown":"https://secwatch.observer/filing/0001799191-23-000006.md","text":"https://secwatch.observer/filing/0001799191-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000006/0001799191-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000006/toi-20230518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:26:18.313519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29285fda46","claim":"Matthew Miller was terminated as Chief Operating Officer at Oncology Institute, Inc..","evidence_excerpt":"In connection with the Company’s termination of its Chief Operating Officer, Matthew Miller, M.D., effective June 16, 2023, on May 18, 2023, the Company notified Dr. Miller of his termination from his position as the Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000006/0001799191-23-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}